Share on LinkedInShare on LinkedIn

ARTICLE · 23 DECEMBER 2025

Market Intelligence Thought Leadership Award Winner

Final Patented Medicines Pricing Guidelines From The PMPRB Take Effect On January 1, 2026: What This Means For Innovative Pharma

McCarthy Tétrault
McCarthy Tétrault
Contributor
McCarthy Tétrault

McCarthy Tétrault

Built on a unique model of collaboration, innovation and efficiency, McCarthy Tétrault delivers...

View firm profile
Explore more from McCarthy Tétrault

Effective January 1, 2026, the Patented Medicine Prices Review Board (PMPRB) will implement new Guidelines for monitoring patented medicine prices in Canada.

CanadaIntellectual Property

Effective January 1, 2026, the Patented Medicine Prices Review Board (PMPRB) will implement new Guidelines for monitoring patented medicine prices in Canada. These Guidelines introduce a two-step review process designed to improve the predictability and administrative efficiency of the PMPRB's processes, while clarifying the PMPRB's role in monitoring rather than regulating prices.

While the Guidelines do not have the force of law, we anticipate that the PMPRB will adhere to them absent special circumstances.

Two-Step Review Process

Step 1: Initial and Annual Review

  • PMPRB compares a patented medicine's Canadian list price to the Highest International Price (HIP) among the PMPRB11 countries [Australia, Belgium, France, Germany, Italy, Japan, Netherlands, Norway, Spain, Sweden, United Kingdom] and also compares price increases against the Consumer Price Index (CPI).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See more popular content from